< View all reports

Gastric and Gastroesophageal Junction Adenocarcinoma (G/GEJAC): Competitive Landscape to 2026

The G/GEJAC pipeline is highly active and evolving; it features 330 products across all stages of clinical development, with monoclonal antibodies prominently featured in Phase III.

Gastric and gastroesophageal junction adenocarcinoma (G/GEJAC) represents the majority of gastric cancer cases worldwide. It is the fifth most diagnosed cancer, and the third most common cause of cancer death in the world. This report is part of our Biosimilars market series.

  • Report Scope:
  • Pipeline Assessment—regional breakdown
  • Clinical Trials Assessment—trial breakdown by phase
  • Commercial Assessment—leading marketed products, current and future players
  • Competitive Landscape Analysis—key market events to 2026

53% of G/GEJAC clinical trials are located in the Asia-Pacific region, with 43% in Japan. The APAC region shows to be a considerable global lead in clinical activity, followed by North America.

Other key findings from this report include the approval of PD-(L)1 modulators is expected to transform the market in future.

As there are no screening programs for these cancers in most of the 8MM (with the exception of Japan) most cases of G/GEJAC are diagnosed at advanced stage, which has poor prognoses. The current G/GEJAC treatment landscape is still very dependent on chemotherapy.

Our Biosimilars market report provides an assessment of the pipeline, clinical, and commercial landscape. Stay ahead of the curve by getting a thorough understanding of the market.

Purchase Today

Single user $ 3,495

Buy Now

+44 (0) 161 359 5813

Not ready to buy yet? Download our free report series guide on the Biosimilars Market

I consent to GlobalData collecting my details provided via this form.

You are in control of the communications you receive from us and you can update your preferences anytime to make sure you are receiving information that matters to you. Please check our GlobalData Privacy Policy to see how we protect and manage your submitted data.